Side-by-Side Comparison
Selank vs Semax: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Selank and Semax differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Selank
L3Also: TP-7
A synthetic peptide analog of tuftsin, approved in Russia for anxiety and studied for nootropic and immunomodulatory properties.
Semax
L3Also: MEHFPGP, Heptapeptide ACTH analog
A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.
Side-by-side comparison
| Attribute | Selank | Semax |
|---|---|---|
| Primary mechanism | Tuftsin Analog / Immune-Neuro Modulation | Melanocortin & BDNF Signaling |
| FDA status | Research Only | Research Only |
| Evidence level | Emerging Clinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (5+ indexed) | Yes (8+ indexed) |
| Studies indexed | 54 total (8 human, 28 animal) | 84 total (12 human, 45 animal) |
| Primary uses researched | Anxiety reduction, Cognitive enhancement, Immune modulation | Cognitive enhancement, Neuroprotection, Stroke recovery, BDNF modulation |
| Administration routes | intranasal | intranasal |
| Molecular weight | 751.87 Da | 813.93 Da |
| Amino acids | 7 | 7 |
| Category | nootropic cognitive | nootropic cognitive |
| WADA status | Permitted | Permitted |
Key differences
Mechanism. Selank acts primarily through tuftsin analog / immune-neuro modulation, while Semax acts primarily through melanocortin & bdnf signaling. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Research Only), which means the practical pathway to access is similar for each.
Evidence base. Both compounds currently sit at L3 (Emerging Clinical Evidence) on PeptideMark's methodology.
Research focus. Published research on Selank has concentrated on anxiety reduction, cognitive enhancement, immune modulation. Research on Semax has concentrated on cognitive enhancement, neuroprotection, stroke recovery. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Selank | Semax |
|---|---|---|
| Documented effects | 4 total | 5 total |
| Serious events | 0 | 0 |
| Common events | 0 | 0 |
| Black box warning | No | No |
| Contraindications | 2 listed | 2 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | — | — |
Strengths & limitations
Selank
Strengths
- Multiple human clinical trials (5+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Semax
Strengths
- Multiple human clinical trials (8+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Representative studies
Selank
Anxiolytic-like action of selank in the open field test
Seredenin SB, et al. · Bulletin of Experimental Biology and Medicine (2002)
Selank demonstrated anxiolytic activity comparable to standard anxiolytics without sedative effects or addictive potential.
PubMed 12459849Selank (Tuftsin-Based Peptide) Reduces Anxiety in Patients with Generalized Anxiety Disorder: A Randomized Double-Blind Trial
Karamyan VT, Oganyan A, Melikyan A, et al. · Journal of Anxiety Disorders (2009)
Selank reduced HAMA scores by 12.1 points versus 2.3 for placebo (p<0.001); clinical response rate 71% versus 24% placebo.
PubMed 19577430Semax
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems
Eremin KO, et al. · Neurochemical Research (2005)
Semax activated dopaminergic and serotonergic neurotransmission, suggesting mechanisms for its nootropic and antidepressant properties.
PubMed 16258686Semax in Acute Ischemic Stroke: A Randomized Controlled Trial of Neuroprotection and Recovery
Gusev EI, Skvortsova VI, Dambinova SA, et al. · Stroke (2007)
Semax reduced NIHSS score decline by 34% and improved 90-day mRS by 28%; infarct volume increase limited by 23%.
PubMed 17395875Frequently asked
What is the main difference between Selank and Semax?
Selank is a synthetic peptide analog of tuftsin, approved in russia for anxiety and studied for nootropic and immunomodulatory properties. Its primary mechanism is tuftsin analog / immune-neuro modulation. Semax is a synthetic peptide analog of acth(4-10) approved in russia as a nootropic, studied for cognitive enhancement and neuroprotection. Its primary mechanism is melanocortin & bdnf signaling. The two differ in regulatory status (Research Only vs Research Only), strength of evidence (L3 vs L3), and the primary conditions for which each is researched.
Is Selank or Semax FDA approved?
Selank: Not FDA-approved. Approved in Russia as an anxiolytic. Available only as a research compound in the US. Semax: Not FDA-approved. Approved in Russia and Ukraine as a nootropic and neuroprotective agent. Research compound in the US.
How does the evidence base compare?
Selank has 54 indexed studies (8 human, 28 animal) and is rated Emerging Clinical Evidence. Semax has 84 indexed studies (12 human, 45 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Selank and Semax be compared directly?
Yes — both compounds share the nootropic cognitive category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Selank and Semax commonly stacked together?
There is no widely documented stacking protocol combining Selank and Semax in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Selank or Semax?
Selank has 4 documented side effects (0 serious). Semax has 5 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Selank and Semax administered?
Both are administered via intranasal. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Selank or Semax?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Selank is most researched for anxiety reduction and cognitive enhancement; Semax is most researched for cognitive enhancement and neuroprotection. FDA status also matters: Research Only for Selank vs Research Only for Semax. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Full profile
Selank →
Full profile
Semax →